全文获取类型
收费全文 | 18762篇 |
免费 | 4948篇 |
国内免费 | 67篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 393篇 |
妇产科学 | 1602篇 |
基础医学 | 140篇 |
口腔科学 | 125篇 |
临床医学 | 15179篇 |
内科学 | 2087篇 |
皮肤病学 | 57篇 |
神经病学 | 593篇 |
特种医学 | 181篇 |
外科学 | 997篇 |
综合类 | 42篇 |
预防医学 | 1651篇 |
眼科学 | 18篇 |
药学 | 59篇 |
中国医学 | 1篇 |
肿瘤学 | 590篇 |
出版年
2024年 | 74篇 |
2023年 | 766篇 |
2022年 | 83篇 |
2021年 | 222篇 |
2020年 | 601篇 |
2019年 | 194篇 |
2018年 | 1064篇 |
2017年 | 1325篇 |
2016年 | 1392篇 |
2015年 | 1461篇 |
2014年 | 1493篇 |
2013年 | 1725篇 |
2012年 | 408篇 |
2011年 | 663篇 |
2010年 | 1035篇 |
2009年 | 1323篇 |
2008年 | 635篇 |
2007年 | 542篇 |
2006年 | 555篇 |
2005年 | 450篇 |
2004年 | 407篇 |
2003年 | 355篇 |
2002年 | 305篇 |
2001年 | 467篇 |
2000年 | 269篇 |
1999年 | 417篇 |
1998年 | 574篇 |
1997年 | 687篇 |
1996年 | 635篇 |
1995年 | 562篇 |
1994年 | 408篇 |
1993年 | 330篇 |
1992年 | 249篇 |
1991年 | 238篇 |
1990年 | 237篇 |
1989年 | 182篇 |
1988年 | 141篇 |
1987年 | 132篇 |
1986年 | 124篇 |
1985年 | 142篇 |
1984年 | 102篇 |
1983年 | 97篇 |
1982年 | 81篇 |
1981年 | 88篇 |
1980年 | 50篇 |
1979年 | 76篇 |
1978年 | 58篇 |
1977年 | 64篇 |
1976年 | 65篇 |
1972年 | 82篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
992.
993.
994.
995.
996.
997.
Jada G. Hamilton PhD MPH Sadie P. Hutson PhD RN WHNP BC Richard P. Moser PhD Sarah C. Kobrin PhD MPH Amy E. Frohnmayer MA Blanche P. Alter MD MPH Paul K. J. Han MD MA MPH 《Annals of behavioral medicine》2013,46(2):204-216
Background
Effects of different sources of medical uncertainty on people’s health-related cognitions, emotions, and decision making have yet to be systematically examined.Purpose
The aim of this study is to examine how uncertainties arising from different sources are associated with decision making regarding stem cell transplantation in Fanconi anemia, a rare, inherited bone marrow failure syndrome that typically presents during childhood.Methods
Data were collected through a cross-sectional survey of 178 parents of 126 Fanconi anemia patients.Results
Two distinct sources of uncertainty were associated with decision outcomes: probability was associated with a lower likelihood of choosing stem cell transplantation, and ambiguity due to conflicting expert opinions was associated with greater decision-making difficulty. Concern about transplantation may mediate these associations.Conclusions
Different sources of uncertainty have different effects on Fanconi anemia treatment decisions, which may be mediated by parents’ emotional reactions. Further research is needed to elucidate these effects and help Fanconi anemia families cope with uncertainty. 相似文献998.
Raja Mehanna MD Christine Hunter RN Anthony Davidson MS Joohi Jimenez‐Shahed MD Joseph Jankovic MD 《Movement disorders》2013,28(2):210-215
Tetrabenazine is effective in the treatment of the chorea associated with Huntington disease and other hyperkinetic movement disorders. Following oral administration, tetrabenazine is hepatically transformed into 2 active metabolites that are CYP2D6 substrates. There are 4 CYP2D6 genotypes: poor metabolizers, intermediate metabolizers, extensive metabolizers, and ultrarapid metabolizers. CYP2D6 genotyping was performed on sequential subjects treated with tetrabenazine, but results were not known at the time of titration. Duration of titration to a stable dose, total daily dose, response rating scores, and adverse events were retrospectively collected and subsequently analyzed. Of 127 patients, the majority (n = 100) were categorized as extensive metabolizers, 14 as intermediate metabolizers, 11 as poor metabolizers, and 2 as ultrarapid metabolizers. Ultrarapid metabolizer patients needed a longer titration (8 vs 3.3, 4.4, and 3 weeks, respectively; P < .01) to achieve optimal benefit and required a higher average daily dose than the other patients, but this difference did not reach statistical significance. The treatment response was less robust in the intermediate metabolizer group when compared with the extensive metabolizer patients (P = .013), but there were no statistically significant differences between the various groups with regard to adverse effects. Our findings demonstrate that, aside from the need for a longer titration in the ultrarapid metabolizers, there are no distinguishing features of patients with various CYP2D6 genotypes, and therefore the current recommendation to systematically genotype all patients prescribed more than 50 mg/day of tetrabenazine should be reconsidered. © 2012 Movement Disorder Society 相似文献
999.
1000.
Christopher G. Goetz MD Glenn T. Stebbins PhD Kathryn A. Chung MD Robert A. Hauser MD MBA Janis M. Miyasaki MD Anthony P. Nicholas MD PhD Werner Poewe MD Klaus Seppi MD Olivier Rascol MD PhD Mark A. Stacy MD John G. Nutt MD Caroline M. Tanner MD PhD Alison Urkowitz MPA Jean A. Jaglin RN Song Ge MS 《Movement disorders》2013,28(3):341-346
Numerous scales assess dyskinesia in Parkinson's disease (PD), variably focusing on anatomical distribution, phenomenology, time, severity, and disability. No study has compared these scales and their relative ability to detect change related to an established treatment. We conducted a randomized placebo‐controlled trial of amantadine, assessing dyskinesia at baseline and at 4 and 8 weeks using the following scales: Unified Dyskinesia Rating Scale (UDysRS), Lang‐Fahn Activities of Daily Living Dyskinesia Rating Scale (LF), 26‐Item Parkinson's Disease Dyskinesia scale (PDD‐26), patient diaries, modified Abnormal Involuntary Movements Scale (AIMS), Rush Dyskinesia Rating Scale (RDRS), dyskinesia items from the Movement Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS), and Clinical Global Impression (severity and change: CGI‐S, CGI‐C). Scale order was randomized at each visit, but raters were aware of each scale as it was administered. Sensitivity to treatment was assessed using effect size. Sixty‐one randomized dyskinetic PD subjects (31 amantadine, 30 placebo) completed the study. Four of the 8 scales (CGI‐C, LF, PDD‐26, and UDysRS) detected a significant treatment. The UDysRS Total Score showed the highest effect size (η2 = 0.138) for detecting treatment‐related change, with all other scales having effect sizes < 0.1. No scale was resistant to placebo effects. This study resolves 2 major issues useful for future testing of new antidyskinesia treatments: among tested scales, the UDysRS, having both subjective and objective dyskinesia ratings, is superior for detecting treatment effects; and the magnitude of the UDysRS effect size from amantadine sets a clear standard for comparison for new agents. © 2012 Movement Disorder Society 相似文献